1. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
M I C H A E L T . O U E L L E T T E
619 East Reeceville Rd ▪ Downingtown, PA 19335
BIOGRAPHY
Accomplished scientist with 17 years experience in small molecule drug discovery. I have a
versatile set of skills in the laboratory while concurrently managing other scientists,
demonstrating leadership at the project level, and capable of influencing scientific strategy.
03/2006 – present SPMB - GlaxoSmithKline Collegeville, PA
Investigator, Group Leader
 Mentor group of 5 scientists working side-by-side with them, providing scientific oversight and
technical guidance. Continually striving to build a team that is extremely versatile and can support
all areas within SPMB
 Manage staff development through objective setting, tracking performance and providing
guidance to create a structured development program
 Demonstrated ability to influence scientific strategy of numerous concurrent projects
serving as project co-leader or individual contributor. Examples of recent programs include
PLCλ2, cccDNA, Matriptase-2, RIPK1, RIPK2
 Demonstrated ability to effectively engage and work across a matrix to accomplish program
objectives and solve problems
 Small molecule drug discovery experience across a broad range of target classes: Kinases, GPCR’s,
Pattern Recognition Receptors, phosholipases, transcription factors, proteases, antiviral targets,
hematological targets
 Individually contribute to program objectives by utilizing broad technical expertise across all
functions of SPMB: Assay development, hit identification, profiling, hit qualification, cell biology,
biochemistry, externalization
 Contributed to candidate selection of more than a half dozen molecules
 Developed and performed series of ELT experiments that led to development of clinical asset
GSK2982772, autoimmune therapy
 Key leader in establishment and evolution of multiple platforms including ELT, qRT-PCR,
centrifugal microtiter plate evacuation, HTS
 Currently working to establish biopharm functional cell assay screening platform within SPMB
 5 years experience in portfolio management, project prioritization, and resource allocation
 HTS Manager: Managed 1/3 of HTS portfolio across multiple DPU/TA’s: Managed flow of HTS
campaigns through screening platforms, ensure transparency of portfolio & status, define and
validate hit identification and triage strategy, manage high throughput screen process, ensure highest
quality data, analyze & communicate data, and track campaign outcomes
 Expertise in integrated hit discovery modalities including HTS, focus screening, fragment
screening, and ELT. Influence project strategy based on biology and project objectives
 Strong analytical skills and ability to work with large datasets: identify patterns, create
fascicle data visualizations, define context, enable data driven decisions
 Serve as scientific mentor to scientists outside of my direct reports as well as mentoring two co-
op students
 Business Expert User (BEU) involved in the enhancement of multiple MDR sponsored IT
assets including ABASE XE, DART, DRAM and MOSAIC

2. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
09/2005 – 03/2006 Molecular Devices Corporation Downingtown, PA
Field Applications Scientist
 Supported the development of high-content screening imaging systems
 Provided training and field support for Transfluor and ImageXpress Micro to potential and
established Molecular Devices customers
 Created User Manual for Transfluor technology
 Responsible for internal training of sales staff regarding the ImageXpress Ultra high-content confocal
imaging system
03/2002 – 09/2005 Xsira Pharmaceuticals Morrisville, NC
Research Associate III – Lead Generation and Progression
 Conducted high throughput screening campaigns to discover compounds that modulate G Protein-
Coupled Receptor desensitization
 Involved in the development, validation, and automation of Transfluor®, a universal cell-based
imaging technology for G-protein Coupled Receptors
 Developed and optimized cell-based and biochemical assays to support internal drug discovery
programs
 Researched, acquired, implemented, and oversaw all HTS automation
 Co-developed a process of scaling up and freezing back large numbers of screen ready cells (2E9) at
high density (40E6 cells/mL)
 Developed storage solution and distribution paradigm for a compound repository of >800,000
chemical compounds
11/1999 – 03/2002 Neurogen Corporation Branford, CT
Research Associate I
 Screened G-Protein Coupled Receptor and ion channel targets in Ca2+ flux functional assays (FLIPR)
and binding assays
 Provided data to drive Lead-op and chemical optimization efforts
 Acted as contact person for the programming, quality control, and service of automated equipment
EDUCATION
09/1995 – 05/1999 University of New Hampshire Durham, NH
 Bachelor of Science in Microbiology; Summa Cum Laude
 Investigated the role of cytokines in the infection of alveolar macrophages by Legionella pneumophila
 Laboratory animal handling, dosing, and tissue harvesting
 Cell culture and sterile technique.
COMPUTER SKILLS
SpotFire, SQL, Microsoft Office – strong Excel skills, eLNB, LotusNotes, ActivityBase, INCA, OR&M,
Discovery Explorer, JMP, GraphPad PRISM, Samuari, DART, DRAM, ELT Enterprise application, BI
PUBLICATIONS
 Xie W, Silvers R, Ouellette M, Wu Z, Lu Q, Li H, Gallagher K, Johnshon K, Montoute M. 2016.
A Luciferase Reporter Gene System for High-Throughput Screening of γ-Globin Gene Activators.
In: High Throughput Screening: Methods & Protocols. Vol. 1439. New York: Springer Science +
Business Media. p. 207-226.
 Harris P, King B, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti C, Cox J, Dare L, Dong
X, Finger J, Grady L, Hoffman S, Jeong J, Kang J, Kasparkova V, Lakdawala A, Lehr R, McNulty D,

3. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
Nagilla R, Ouellette M, Pao C, Rendina A, Schaeffer M, Summerfield J, Swift B, Totoritis R, Ward
P, Zhang A, Zhang D, Marquis R, Bertin J, Gough J (2016) DNA-Encoded Library Screening
Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting
Protein 1 Kinase Inhibitors. Journal of Medicinal Chemistry, 59(5): 2163-78
 Haile P, Votta B, Marquis R, Bury M, Mehlmann J, Singhaus R, Charnley A, Lakdawala A, Convery
M, Lipshutz D, Desai B, Swift B, Capriotti C, Berger S, Mahajan M, Reilly M, Rivera E, Sun H,
Nagilla R, Beal A, Finger J, Cook M, King B, Ouellette M, Totoritis R, Pierdomenico M, Negroni
A, Stronati L, Cucchiara S, Ziokowski B, Vossenkamper A, MacDonald T, Gough P, Bertin J,
Casillas L (2016) The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-
N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of
RIP2 Kinase. Journal of Medicinal Chemistry, 59(10): 4867-80
 Berger SB, Harris P, Nagilla R, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, Capriotti
C, Ouellette M, King BW, Wisnoski D, Cox J, Reilly M, Marquis RW, Bertin J, Gough PJ (2015)
Characterization of GSK’963: A Structurally Distinct, Potent and Selective Inhibitor of RIP1 Kinase.
Cell Death Discovery, 15009(1).
 Charnley A, Convery M, Lakdawala A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R,
Schwartz B, King B, Wisnoski D, Kang J, Eidam P, Votta B, Gough P, Marquis R, Vertin J, Casillas
L (2015) Crystal Structures of Human RIPK2 Kinase Catalytic Domain Complexed With ATP-
Competitive Inhibitors: Foundations for Understanding Inhibitor Selectivity. Bioorganic Medicinal
Chemistry, 23(21): 7000-6
 Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, Lich JD, Finger J, Kasparcova V,
Votta B, Ouellette M, King BW, Wisnoski D, Lakdawala AS, DeMartino MP, Casillas LN, Haile
PA, Sehon CA, Marquis RW, Upton J, Daley-Bauer LP, Roback L, Ramia N, Dovey CM, Carette JE,
Chan FK, Bertin J, Gough PJ, Mocarski ES, Kaiser WJ (2014) RIP3 Induces Apoptosis Independent
of Pronecrotic Kinase Activity. Molecular Cell, 56(4): 481-95
 Harris P, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti C, Cox J, Dare L, Finger J,
Hoffman S, Kahler K, Lehr R, Lich J, Nagilla R, Nolte R, Ouellette M, Pao C, Schaeffer M,
Smallwood A, Sun H, Swift B, Totoritis R, Ward P, Marquis R, Bertin J, Gough J (2013) Discovery
of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with
Necroptosis. ACS Medicinal Chemistry Letters, 4(12): 1238-43
PRESENTATIONS & POSTERS
 Ouellette M. RIPK1 Small Molecule Discovery Case Study. Oral presentation at
GlaxoSmithKline Drug Design & Selection Seminar Series 2016: Collegeville, PA 19426
 Ouellette M, Kallal L, Steiginga M, Graybill T, Bandyopadhyay D, Widdowson K, Pope A,
Akabas M. A Novel Yeast Based Assay to Discover Inhibitors of P. falciparum Nucleoside
Transporter ENT1. Poster presented at GSK Sharing Science Day 2015
 Cottom J, Ouellette M. Increased HTRF pre-read delay time reduces hit rate by eliminating many e
optical interference compounds. Poster presented at UP Sharing Science Day 2015
 Montoute M, Bee T, Ouellette M, Hofmann G, Wu Z, Gore L, Benowitz A, Gilmartin A, Boyer J.
Identification of Novel Hemoglobin-γ Inducers Through a Disease Relevant Phenotypic Screen
With Annotated Compound Library. Poster presented at UP Sharing Science Day 2015
 BandyopadhyayD, Ouellette M, Scavello G, ChakravortyS, RamanjuluJ, Martens S.
Enhancing Hit-to-Lead with SAR extracted from Screening Datasets using Scaffold Detection
and R-Group analysis. Poster presented at GSK Science Day 2013
 Ouellette M, Cox J, Gao E, Wu Z, Casillas L, Ogden C, Votta B. RIPK2: Discovery in Partner-
Ship with the PRR-DPU. GSK 2013: King of Prussia, PA 19406
 Ouellette M. Sequence to Structure – Decoding the DNA Encoded Library. Oral presentation
at GSK Science Forum 2008: King of Prussia, PA 19406
 Cowan C, Ouellette M, Payne R, Hudson C, Eckhardt A, Oakley R. Process Improvements in
Cell Delivery for GPCR High Throughput Screening. Oral presentation at Society for

4. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
Biomolecular Screening 2004: Orlando, FL 32801
 Rhem S, Sherman B, Ouellette M, Cowan C. Comparison of Compound Characterization with
Transfluor and AlphaScreen. Poster presented at Society for Biomolecular Screening 2004:
Orlando, FL 32801
 Ouellette M, Rhem S, Sherman B, Geraghty C, Meyers D, Cruickshank R, Cowan C.
Development, Conduct and Results of Two High Throughput Screens Using Transfluor
Technology. Poster